What Crescent Biopharma Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 2 |
| Sells | 9 | 16 |
| Total trades | 9 | 34 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 34 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| McNeill Jonathan | President and COO | Sep 18 | Sale for tax withholding · S | −3,839 | $16.71 | −$64.1K | 134,588 |
| Brumm Joshua T | Chief Executive Officer | Sep 18 | Sale for tax withholding · S | −7,837 | $16.71 | −$131K | 271,765 |
| Im Ellie Eunkyung | Chief Medical Officer | Sep 16 | Sale for tax withholding · S | −623 | $17.90 | −$11.2K | 21,446 |
| McNeill Jonathan | President and COO | Sep 16 | Sale for tax withholding · S | −731 | $17.90 | −$13.1K | 138,427 |
| Lynch Ryan | See Remarks | Sep 16 | Sale for tax withholding · S | −240 | $17.90 | −$4.3K | 13,631 |
| Brumm Joshua T | Chief Executive Officer | Sep 16 | Sale for tax withholding · S | −1,610 | $17.90 | −$28.8K | 279,602 |
| Bispham Barbara Harlin | See Remarks | Sep 16 | Sale for tax withholding · S | −620 | $17.90 | −$11.1K | 18,710 |
| Scalzo Richard William | Chief Financial Officer | Sep 16 | Sale for tax withholding · S | −568 | $17.90 | −$10.2K | 19,730 |
| Pinkas Jan | Chief Scientific Officer | Sep 16 | Sale for tax withholding · S | −658 | $17.90 | −$11.8K | 21,581 |
| Fairmount Funds Management Llc | Director | Jul 16 | Open-market buy · P | +853,450 | $14.50 | +$12.4M | 3,601,316 |
| Bispham Barbara Harlin | See Remarks | Jun 22 | Sale for tax withholding · S | −1,218 | $17.99 | −$21.9K | 19,330 |
| Brumm Joshua T | Chief Executive Officer | Jun 22 | Sale for tax withholding · S | −42,305 | $17.99 | −$761K | 281,212 |
| Im Ellie Eunkyung | Chief Medical Officer | Jun 22 | Sale for tax withholding · S | −1,219 | $17.99 | −$21.9K | 22,069 |
| Scalzo Richard William | Chief Financial Officer | Jun 22 | Sale for tax withholding · S | −1,112 | $17.99 | −$20K | 20,298 |
| McNeill Jonathan | President and COO | Jun 22 | Sale for tax withholding · S | −20,549 | $17.99 | −$370K | 139,158 |
| Lynch Ryan | See Remarks | Jun 22 | Sale for tax withholding · S | −465 | $17.99 | −$8.37K | 13,871 |
| Pinkas Jan | Chief Scientific Officer | Jun 22 | Sale for tax withholding · S | −1,288 | $17.99 | −$23.2K | 22,239 |
| Pinkas Jan | Chief Scientific Officer | Dec 15 | Grant / award · A | +5,000 | — | — | 22,507 |
| Pinkas Jan | Chief Scientific Officer | Dec 15 | Grant / award · A | +17,507 | — | — | 17,507 |
| Lynch Ryan | See Remarks | Dec 15 | Grant / award · A | +4,000 | — | — | 12,378 |
Loading...
